Sodium butyrate


CAS No. : 156-54-7

(Synonyms: Butanoic acid (sodium); Butyric acid (sodium))

156-54-7
Price and Availability of CAS No. : 156-54-7
Size Price Stock
500g $39 In-stock
1000g $60 In-stock
> 2 kg Get quote
We match the lowest price on market.

We offer a substantial discount on larger orders, please inquire via [email protected]

or Fax: (86)21-58955996

Inquiry for price and availability only. Please place your order via our email or fax.

Cat. No. : HY-B0350A
M.Wt: 110.09
Formula: C4H7NaO2
Purity: >98 %
Solubility: H2O : 100 mg/mL (ultrasonic)
Introduction of 156-54-7 :

Sodium butyrate ((Butanoic acid; Butyric acid) sodium) is an orally active HDAC inhibitor. Sodium butyrate induces hyperacetylation of core histones and affects phosphorylation of H1/H2A, thereby altering chromatin structure and regulating gene expression. Sodium butyrate can be used in research related to various cancers, inflammatory bowel disease, and sickle cell anemia[1][2][3][4][5][6]. IC50 & Target:HDAC[1] In Vitro:Butyric acid (1-20 mM; 24 h) induces extensive DNA degradation and apoptosis in U1 and ACH-2 cells, reduces tumor proliferation, and induces morphological changes associated with apoptosis in human colon tumor cell lines[2].

Butyric acid sodium (1 mM; 1-7 days) enhances secretion of plasma plasminogen activator, activities of cathepsin B and L, and promotes homotypic cell aggregation in cloned low-metastatic P-29 cells[5].
Butyric acid sodium (1.5 mM; 31 h) induces G1-phase cell cycle arrest in erythroleukemic cells[2].
Butyric acid (1.5 mM; 3-6 days) reduces 3H-IdUR incorporation, increases cell adhesion, and significantly enhances the migration and invasion abilities of B16a cells in mouse B16a and K-1735 cells[6].
Butyric acid (0.1-1.0 mM; 12 days) exerts an inhibitory effect on clonal growth in granulocyte-macrophage progenitor cells of chronic myeloid leukemia (CML)[3].
Butyric acid (2.5-5 mM; 24-48 h) induces a morphological change from spherical to flattened shape in chicken embryo chondrocytes, and inhibits cartilage-specific chondroitin sulfate proteoglycan (CSPG) and DNA synthesis[4]. In Vivo:Butyric acid (1-2 g/kg/day) increases fetal hemoglobin levels in reticulocytes in non-anemic baboon models[2].
Butyric acid (5 mg/pellet; subcutaneous implantation; single implantation, 1 day prior to cell injection; observation for 21 days) significantly reduces the number of pulmonary metastatic nodules in the C57BL/6 mouse metastasis model with tail vein injection of B16a melanoma cells[6].
Butyric acid sodium (100 mM; i.g.; once daily; for 4 months) exerts effects of ameliorating bone microstructure damage, repairing intestinal barrier, and upregulating the proportion of bone marrow Treg cells in the osteoporosis model of C57BL/6J mice with chronic lead exposure[1].

Your information is safe with us.